China’s Xi speaks with Trump by phone, discusses Taiwan and bilateral ties
Tenax Therapeutics, Inc. (NASDAQ:TENX) Interim CFO Thomas McGauley reported purchasing shares of common stock on November 17, 2025. The transactions, totaling $58,164, involved the purchase of shares at prices ranging from $7.228 to $7.35. The insider purchase comes as TENX shares trade at $7.32, near the CFO’s acquisition price. According to InvestingPro data, the stock has delivered an impressive 53.46% return over the past year despite being currently considered overvalued based on Fair Value estimates.
McGauley acquired 2,000 shares directly at a weighted average price of $7.337, with individual prices ranging from $7.14 to $7.43. He also indirectly acquired 1,000 shares through his child at $7.35 per share, and 5,000 shares through his spouse at a weighted average price of $7.228, with individual prices ranging from $7.17 to $7.30. This insider confidence comes as analysts maintain a bullish consensus on TENX with price targets ranging from $10 to $30, significantly above current trading levels. InvestingPro identifies 15 additional investment insights for Tenax, including that the company holds more cash than debt and maintains strong liquidity with current assets exceeding short-term obligations.
In other recent news, Piper Sandler has initiated coverage on Tenax Therapeutics with an Overweight rating and set a price target of $20.00. The research firm emphasized Tenax’s development of TNX-103, an oral treatment for pulmonary hypertension with heart failure with preserved ejection fraction. The Phase 3 LEVEL trial results for this treatment are anticipated in the second half of 2026. These developments reflect Piper Sandler’s positive outlook on Tenax Therapeutics. The initiation of coverage suggests confidence in the company’s future potential. Analysts from Piper Sandler appear optimistic about the company’s pipeline and its implications for future growth. This coverage is part of recent developments concerning Tenax Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.